BL
INZY

BFSG LLC’s Inozyme Pharma INZY Stock Holding History

BFSG LLC’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-500
Closed -$2.62K – 678
2024
Q3 		$2.62K Hold
500
– – ﹤0.01% 578
2024
Q2 		$2.23K Hold
500
– – ﹤0.01% 573
2024
Q1 		$3.83K Buy
+500
New +$2.74K ﹤0.01% 561

Other funds holding INZY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BFSG LLC's INZY Position: Q4 2024 in Review

BFSG LLC sold out of Inozyme Pharma (INZY) in Q4 2024, closing a stake of 500 shares — an estimated $2.62K sold.

BFSG LLC first reported a position in INZY in Q1 2024 and held it in 3 quarters. The position peaked at $3.83K in Q1 2024. 105 funds tracked by Wall St. Rank hold INZY as of Q4 2024.

  • BFSG LLC reported no remaining Inozyme Pharma position as of Q4 2024 after selling out during the quarter.
  • BFSG LLC sold 500 Inozyme Pharma shares in Q4 2024, an estimated $2.62K.
  • BFSG LLC first reported a position in Inozyme Pharma in Q1 2024 and held it in 3 quarters.
  • BFSG LLC's Inozyme Pharma position peaked at $3.83K in Q1 2024.
  • 105 funds tracked by Wall St. Rank held Inozyme Pharma as of Q4 2024.

Based on BFSG LLC's 13F filing for Q4 2024, filed 31 Jan 2025.